ABSTRACT
Abstract .............................................................................................................227 Metabolic Syndrome .........................................................................................228 Metabolic Syndrome and Cardiovascular Disease ...........................................228 Metabolic Syndrome and Diabetes...................................................................229 Inflammation, Metabolic Syndrome, and Acute Phase Proteins......................229 Pro-Inflammatory Cytokines, Monocytes, and Metabolic Syndrome..............230 Adipose Tissue and Inflammation ....................................................................231 Therapeutic Modulation of Inflammation in Metabolic Syndrome .................232 Weight Loss, Hypocaloric Diets, Inflammation, and Metabolic Syndrome....232 Pharmacological Therapies with Potential to Prevent or Treat
Metabolic Syndrome ...............................................................................237 Conclusion.........................................................................................................238 References .........................................................................................................238
Metabolic syndrome (MetS) is a disorder composed of central adiposity, dyslipidemia, abnormal glucose tolerance, and hypertension. It confers an increased risk for diabetes and cardiovascular disease (CVD). Inflammation plays a pivotal role in atherosclerosis and is involved in abnormalities associated with MetS such as insulin resistance (IR) and adiposity. The various biomarkers of inflammation such as inflammatory cytokines (TNF-
